T cells, also called T lymphocytes, are an integral component of the adaptive immune system which seek out and eliminate foreign particles. Functions of T cells include killing infected host cells, activating other immune cells, producing and releasing immune messengers called cytokines into the body, and regulating the immune response. When T cell functionality is hindered by disease, genetics, or environment, the immune system could be at severe risk.
Gene editing experts within MilliporeSigma’s Cell Design Studio™ provide premier custom cell line engineering services to create and deliver unique cell-based assays tailored for...
Learning Objectives: 1. Understand how the outcome of PD-1 blockade is a summation of increased Teffector activity and increased Treg suppressive activity 2. Explain how PD-1 blockade leads...
Learning Objectives: 1. Learn about why Luminex’s xMAP bead-based technology is the gold-standard in multiplexing, including how xMAP emerged as the leading multiplexing platform for l...
Chimeric antigen receptor (CAR) T cells have demonstrated significant success in treating relapsed or treatment-refractory hematologic malignancies in the clinic, inducing remissions in 70-9...
Despite the promising results with current approved immunotherapies, all patients do not have the same level of response, and recent efforts have focused on understanding and avoiding immuno...
Learning Objectives: 1. Define “universal CARs” and describe their mechanism of action. 2. Explain current challenges in CAR T cell therapy. 3. Describe potential benefits and ch...
Learning Objectives: 1. Define the impact of PD-L1 expressed on non-tumor, non-hematopoietic cells in T cell-mediated tumor control 2. Reveal the contribution of IFNg signaling in dermal lym...
Progress developing immune-based treatments to treat the highly lethal pancreatic ductal adenocarcinoma (PDA) has lagged behind other cancer types. This may be due, in part, to a fibroinflam...
Immune checkpoint therapy (ICT) is a front-line treatment for lung cancer; however, low mutational burden and ‘non-T cell inflamed’ signatures predict poor responses to ICT in ~5...
Rhabdomyosarcoma (RMS) is a soft tissue cancer commonly arising in muscle and is the most common soft tissue cancer in children. Patients with metastatic RMS have a poor prognosis that has n...
Proximity Ligation Assay (PLA), is a powerful technique for demonstrating the presence of 2 unique targets in direct proximity of each other in tissue sections. It allows visualization of in...
Engineered cell therapy is an emerging field of science to target and treat cancer. Current strategies include utilizing immune cells such as T cells, NK cells and Macrophages or other cells...
Date: April 15, 2021 Time: 8:00am PST Stem cell’s unique properties confer them a multitude of potential applications in the fields of cellular therapy, disease modelling and drug scre...
Cell therapies, including chimeric antigen receptor (CAR) T-cell therapy, are emerging as promising treatments, especially for hematological malignancies. However, many challenges remain in...
DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
DATE: January 27, 2021 TIME: 9am PST Well-timed interaction of correctly functioning maternal immune cells is essential to facilitate healthy placenta formation, as the uterine immune enviro...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 and has spread globally, causing a pandemic of respiratory illness designated coronavirus disease 20...
Date: November 19, 2020 Time: 8:00am PST, 11:00am EST Monoclonal antibody-based drugs have shown great potential as a treatment for several cancers. At Miltenyi Biotec, we offer a complete wo...
Date: November 17, 2020 Time: 8:00am COVID-19 is a complex pathological condition caused by infection with SARS-CoV. Different features have been observed in patients with a severe dis...
Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
DATE: November 5, 2020 TIME: 9:00am (PDT), 12:00pm (EDT) With accelerating development and approval of cell therapies, biologic drugs, and antiviral treatments comes a need for more robust a...
DATE: November 4th, 2020 TIME: 11:00am PST As cell therapies become more complex, the need for robust analytical tools to characterize such products as they enter the clinic has increased in...
DATE: Novemb 3, 2020 TIME: 8:00am PST, 11:00am EST Following on from Miltenyi Biotec’s renowned webinar “Improve your CAR T cell research”, this webinar covers our latest p...
Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
Gene editing experts within MilliporeSigma’s Cell Design Studio™ provide premier custom cell line engineering services to create and deliver unique cell-based assays tailored for...
Learning Objectives: 1. Understand how the outcome of PD-1 blockade is a summation of increased Teffector activity and increased Treg suppressive activity 2. Explain how PD-1 blockade leads...
Learning Objectives: 1. Learn about why Luminex’s xMAP bead-based technology is the gold-standard in multiplexing, including how xMAP emerged as the leading multiplexing platform for l...
Chimeric antigen receptor (CAR) T cells have demonstrated significant success in treating relapsed or treatment-refractory hematologic malignancies in the clinic, inducing remissions in 70-9...
Despite the promising results with current approved immunotherapies, all patients do not have the same level of response, and recent efforts have focused on understanding and avoiding immuno...
Learning Objectives: 1. Define “universal CARs” and describe their mechanism of action. 2. Explain current challenges in CAR T cell therapy. 3. Describe potential benefits and ch...
Learning Objectives: 1. Define the impact of PD-L1 expressed on non-tumor, non-hematopoietic cells in T cell-mediated tumor control 2. Reveal the contribution of IFNg signaling in dermal lym...
Progress developing immune-based treatments to treat the highly lethal pancreatic ductal adenocarcinoma (PDA) has lagged behind other cancer types. This may be due, in part, to a fibroinflam...
Immune checkpoint therapy (ICT) is a front-line treatment for lung cancer; however, low mutational burden and ‘non-T cell inflamed’ signatures predict poor responses to ICT in ~5...
Rhabdomyosarcoma (RMS) is a soft tissue cancer commonly arising in muscle and is the most common soft tissue cancer in children. Patients with metastatic RMS have a poor prognosis that has n...
Proximity Ligation Assay (PLA), is a powerful technique for demonstrating the presence of 2 unique targets in direct proximity of each other in tissue sections. It allows visualization of in...
Engineered cell therapy is an emerging field of science to target and treat cancer. Current strategies include utilizing immune cells such as T cells, NK cells and Macrophages or other cells...
Date: April 15, 2021 Time: 8:00am PST Stem cell’s unique properties confer them a multitude of potential applications in the fields of cellular therapy, disease modelling and drug scre...
Cell therapies, including chimeric antigen receptor (CAR) T-cell therapy, are emerging as promising treatments, especially for hematological malignancies. However, many challenges remain in...
DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
DATE: January 27, 2021 TIME: 9am PST Well-timed interaction of correctly functioning maternal immune cells is essential to facilitate healthy placenta formation, as the uterine immune enviro...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 and has spread globally, causing a pandemic of respiratory illness designated coronavirus disease 20...
Date: November 19, 2020 Time: 8:00am PST, 11:00am EST Monoclonal antibody-based drugs have shown great potential as a treatment for several cancers. At Miltenyi Biotec, we offer a complete wo...
Date: November 17, 2020 Time: 8:00am COVID-19 is a complex pathological condition caused by infection with SARS-CoV. Different features have been observed in patients with a severe dis...
Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
DATE: November 5, 2020 TIME: 9:00am (PDT), 12:00pm (EDT) With accelerating development and approval of cell therapies, biologic drugs, and antiviral treatments comes a need for more robust a...
DATE: November 4th, 2020 TIME: 11:00am PST As cell therapies become more complex, the need for robust analytical tools to characterize such products as they enter the clinic has increased in...
DATE: Novemb 3, 2020 TIME: 8:00am PST, 11:00am EST Following on from Miltenyi Biotec’s renowned webinar “Improve your CAR T cell research”, this webinar covers our latest p...
Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
